Table 3.
Complications and treatment in 465 patients with SARS‐CoV‐2 infection
| Variable | Value |
|---|---|
| No. of patients (%) | |
| Complications | |
| Acute respiratory distress syndrome | 11(2.37%) |
| Shock | 1 (0.22%) |
| Liver injury | 61(13.12%) |
| Treatment | |
| Anticoronavirus treatment | 387 (83.23%) |
| Interferon‐α + lopinavir/ritonavir + arbidol | 142 (36.70%) |
| Interferon‐α + lopinavir/ritonavir | 115 (29.72%) |
| Lopinavir/ritonavir | 39 (10.08%) |
| Lopinavir/ritonavir + arbidol | 32 (8.27%) |
| Time from onset of illness to administration of antiviral therapy | |
| 0‐2 days | 115 (29.72%) |
| 3‐4 days | 108 (27.91%) |
| 5‐6 days | 70 (18.09%) |
| >6 days | 94 (24.29%) |
| Oxygen therapy | 445 (95.70%) |
| Mechanical ventilation | |
| Non‐invasive | 4 (0.86%) |
| Invasive | 4 (0.86%) |
| CRRT | 0 |
| ECMO | 0 |
| Glucocorticoids | 60 (12.90%) |
| Time from onset of illness to Glucocorticoid administration (days, mean ± SD) | 6.93 ± 3.34 |
| Dosage (mg) (interquartile range) | 40 (40‐80) |
| IVIG | 42 (9.03%) |
| Dosage (g) (interquartile range) | 20 (16.25‐20) |
| Antibiotic treatment | 218 (46.88%) |
| Admission to intensive care unit | 4（0.86%） |
Abbreviations: CRRT, continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; IVIG: intravenous immunoglobulin.